Revance price target lowered to $12 from $15 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Revance Therapeutics to $12 from $15 and keeps a Buy rating on the shares. The analyst says investor confidence in Revance “was shaken” when the company abruptly shifted its pricing strategy for Daxxify and Q4’s performance fell short of consensus. However, the firm sees little downside in Revance shares from current levels given low expectations and a cheap valuation.